These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

129 related items for PubMed ID: 10715287

  • 1. Examining the role of neoadjuvant androgen deprivation in patients undergoing prostate brachytherapy.
    Potters L, Torre T, Ashley R, Leibel S.
    J Clin Oncol; 2000 Mar; 18(6):1187-92. PubMed ID: 10715287
    [Abstract] [Full Text] [Related]

  • 2. Isotope selection for patients undergoing prostate brachytherapy.
    Cha CM, Potters L, Ashley R, Freeman K, Wang XH, Waldbaum R, Leibel S.
    Int J Radiat Oncol Biol Phys; 1999 Sep 01; 45(2):391-5. PubMed ID: 10487561
    [Abstract] [Full Text] [Related]

  • 3. Risk profiles to predict PSA relapse-free survival for patients undergoing permanent prostate brachytherapy.
    Potters L, Cha C, Oshinsky G, Venkatraman E, Zelefsky M, Leibel S.
    Cancer J Sci Am; 1999 Sep 01; 5(5):301-6. PubMed ID: 10526671
    [Abstract] [Full Text] [Related]

  • 4. A comprehensive review of CT-based dosimetry parameters and biochemical control in patients treated with permanent prostate brachytherapy.
    Potters L, Cao Y, Calugaru E, Torre T, Fearn P, Wang XH.
    Int J Radiat Oncol Biol Phys; 2001 Jul 01; 50(3):605-14. PubMed ID: 11395226
    [Abstract] [Full Text] [Related]

  • 5. The role of external radiotherapy in patients treated with permanent prostate brachytherapy.
    Potters L, Fearn P, Kattan M.
    Prostate Cancer Prostatic Dis; 2002 Jul 01; 5(1):47-53. PubMed ID: 15195130
    [Abstract] [Full Text] [Related]

  • 6. Predictors of improved outcome for patients with localized prostate cancer treated with neoadjuvant androgen ablation therapy and three-dimensional conformal radiotherapy.
    Zelefsky MJ, Lyass O, Fuks Z, Wolfe T, Burman C, Ling CC, Leibel SA.
    J Clin Oncol; 1998 Oct 01; 16(10):3380-5. PubMed ID: 9779716
    [Abstract] [Full Text] [Related]

  • 7. Prognostic significance of race on biochemical control in patients with localized prostate cancer treated with permanent brachytherapy: multivariate and matched-pair analyses.
    Lee LN, Barnswell C, Torre T, Fearn P, Kattan M, Potters L.
    Int J Radiat Oncol Biol Phys; 2002 Jun 01; 53(2):282-9. PubMed ID: 12023131
    [Abstract] [Full Text] [Related]

  • 8. Five-year biochemical outcome following permanent interstitial brachytherapy for clinical T1-T3 prostate cancer.
    Merrick GS, Butler WM, Galbreath RW, Lief JH.
    Int J Radiat Oncol Biol Phys; 2001 Sep 01; 51(1):41-8. PubMed ID: 11516849
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Biochemical relapse-free survival in 400 patients treated with I-125 prostate brachytherapy: the Guildford experience.
    Nobes JP, Wells IG, Khaksar SJ, Money-Kyrle JF, Laing RW, Langley SE.
    Prostate Cancer Prostatic Dis; 2009 Sep 01; 12(1):61-6. PubMed ID: 18427571
    [Abstract] [Full Text] [Related]

  • 11. The prognostic significance of Gleason Grade in patients treated with permanent prostate brachytherapy.
    Potters L, Purrazzella R, Brustein S, Fearn P, Huang D, Leibel SA, Kattan MW.
    Int J Radiat Oncol Biol Phys; 2003 Jul 01; 56(3):749-54. PubMed ID: 12788181
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Influence of body mass index on biochemical outcome after permanent prostate brachytherapy.
    Merrick GS, Butler WM, Wallner KE, Galbreath RW, Allen Z, Lief JH, Adamovich E.
    Urology; 2005 Jan 01; 65(1):95-100. PubMed ID: 15667872
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. No apparent benefit at 5 years from a course of neoadjuvant/concurrent androgen deprivation for patients with prostate cancer treated with a high total radiation dose.
    Martinez A, Galalae R, Gonzalez J, Mitchell C, Gustafson G, Kovacs G.
    J Urol; 2003 Dec 01; 170(6 Pt 1):2296-301. PubMed ID: 14634400
    [Abstract] [Full Text] [Related]

  • 17. Biochemical (prostate-specific antigen) relapse-free survival and toxicity after 125I low-dose-rate prostate brachytherapy.
    Khaksar SJ, Laing RW, Henderson A, Sooriakumaran P, Lovell D, Langley SE.
    BJU Int; 2006 Dec 01; 98(6):1210-5. PubMed ID: 17034501
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Lack of benefit from a short course of androgen deprivation for unfavorable prostate cancer patients treated with an accelerated hypofractionated regime.
    Martinez AA, Demanes DJ, Galalae R, Vargas C, Bertermann H, Rodriguez R, Gustafson G, Altieri G, Gonzalez J.
    Int J Radiat Oncol Biol Phys; 2005 Aug 01; 62(5):1322-31. PubMed ID: 16029788
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.